CEO's On the Move
Meridian Energy Limited Announces Retirement of Mark Binns as CEO, Effective December 21, 2017
Meridian Energy Limited
:New Zealand Stock Exchange) Chris Moller, the Chairman of Meridian Energy, confirmed that he has received notice from chief executive Mark Binns of his intention to retire. Mark Binns is giving six months' notice, noting December 21 as the effective date of his resignation.
Upcoming Board Meetings
June 23, 2017
Inabata & Co.,Ltd., Board Meeting, Jun 23, 2017. Agenda: To consider the change to its representative directors.
Inabata & Co.,Ltd. Key Board Members
Senior Managing Executive Officer, Chief of Overseas Business Office, General Manager...
Managing Executive Officer, Deputy Chief of Overseas Business Office and Director
Rea Group Ltd Appoints Henry Ruiz as Chief Executive Officer of REA Group Asia
REA Group Ltd. has appointed Henry Ruiz as Chief Executive Officer (CEO) for REA Group Asia with immediate effect. Ruiz, who has been acting in the position since March 2017, was responsible for the group's Asian business, including iProperty Group across South-East Asia and Chinese property site, myfun.com. He reports to REA Group CEO Tracey Fellows and retains his position on the board of PropTiger.
Biohaven Pharmaceutical Holding Company Ltd. and Biohaven Pharmaceuticals, Inc. Announce Executive Appointments
Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) and its wholly owned subsidiary, Biohaven Pharmaceuticals Inc. announced recent key additions to its senior leadership team as it develops an expanded portfolio of therapeutic candidates across multiple neurological disorders. Elyse Stock, M.D. has been appointed as the company's Chief of Portfolio Strategy and Development, and St. John (Donnie) McGrath, M.D. has been appointed as Chief of Corporate Strategy and Business Development. Dr. Stock has more than 30 years of clinical and drug development experience. She was most recently Vice-President Global Development Leader at Bristol-Myers Squibb (BMS), where she worked for the last 19 years in various positions developing numerous investigational agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular disease. Dr. McGrath has more than 22 years of pharmaceutical industry experience, including the involvement in the execution of numerous in-licensing and out-licensing agreements and business acquisitions. He joins Biohaven from BMS, where he most recently served as Vice President of Business Development and Head of Search & Evaluation. In addition, Dr. McGrath was responsible for overseeing BMS' venture capital investment portfolio and provided leadership for all global external partnering activities. Before joining the business development group, Dr. McGrath was the BMS global development lead for REYATAZ®.
Masan Group Corporation Announces the Resignation of Le Trung Thanh as Deputy CEO
On June 19, 2017, BODs of MaSan Group Corporation approved the resignation of Mr. Le Trung Thanh as Deputy CEO as from June 19, 2017.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Top Compensated Executives at undefined
|Compensation as of Fiscal Year 2016. All Compensation is in USD.|
Average Compensation in the Independent Power and Renewable Electricity Producers Industry